Navigation Links
Genesis Biosystems Unveils Innovative Skin Treatment at Esthétique SPA International Trade Show
Date:2/12/2013

how to use the system and educate their clients.

About Esthétique Spa International
Esthétique Spa International (ESI) offers the best education at the most affordable price in the spa and wellness industry.

Spa professionals gather at ESI events all over North America for practical business solutions, trend information and the latest offerings and insights from leading industry suppliers. For more than 20 years, ESI has been organized by tradeshow veterans Bernard Renaud and Robert Lamarche.

ESI attracts qualified visitors from North America and abroad. Personal attention, quality education and a carefully-chosen show floor of quality exhibitors are the hallmarks of all their shows. Comprehensive educational programs featuring renowned industry-leaders and curated show floor attract spa owners, managers, estheticians, massage therapists and medical professionals looking to expand their spa and esthetic services.

ESI events are focused exclusively on owners, directors and professionals in the aesthetic, spa and wellness industries. Only companies pertinent to the industry are invited to exhibit at ESI shows. For more information about the show visit http://spashowusa.com/.

About Genesis Biosystems
Genesis Biosystems Inc., a certified ISO 13485 manufacturer, produces quality aesthetic and biomedical products, including Derma Genesis® Microdermabrasion Systems for medical grade microdermabrasion treatments, DermaFrac™ Dermal Micro-Channeling infusion systems, LipiVage® Fat Transfer Systems and the AccelaFuze™ Combination Therapy System. Visit genesisbiosystems.com or call (888) 577-7335 for more information.

Read the full story at http://www.prweb.com/releases/2013/2/prweb1041919
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
2. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
3. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
4. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
5. Genesis Biopharma Issues Letter To Shareholders
6. Genesis Biopharma Mentioned Favorably in BioMedReports Article
7. Organogenesis Announces Annual College Scholarship Award Winner
8. Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series
9. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
10. AyoxxA Biosystems Closes Series A Financing Round
11. Aushon BioSystems and AH diagnostics Sign Distribution Deal for Scandinavia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
(Date:1/14/2014)... Holloway America today announced an addition to ... (MTRs) for all pressure vessels and tank parts the ... important for equipment that must meet ASME, CE, PED, ... functionality that allows authorized users to quickly locate and ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... ChanTest, the leading expert in ion channels and ... development, and safety -- is one of eight organizations ... and Commercialization Program. Governor Ted Strickland and Interim Director ... the Ohio Third Frontier Commission, Mark Barbash, announced the ...
... Aegera Therapeutics is pleased to announce the initiation ... AEG33773, a novel, orally bio-available small molecule therapeutic ... , The Phase 2a study, entitled A Multicenter, ... Efficacy of AEG33773 versus Placebo in Patients with ...
... May 6 iZumi Bio, Inc., a biotechnology ... stem cell (iPS) technology with the mission of ... differentiation of patient cells, today announced the appointments ... (CTO) and Dushyant Pathak, Ph.D., as vice president ...
Cached Biology Technology:ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 3
(Date:4/17/2014)... and fragmentation of forests in the Amazon help ... contributing to rapid and widespread forest loss during ... The findings show that forests in the Amazon ... coupled with forest fires lead to large-scale loss ... Balch, assistant professor of geography, Penn State. , ...
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
(Date:4/17/2014)... Australian National University (ANU), have developed a new ... variability over the past 5.3 million years., The ... surrounding ice ages over the past two million ... carbon dioxide levels, global temperatures and sea levels., ... (UoS) and the National Oceanography Centre (NOC) in ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Ancient sea-levels give new clues on ice ages 2
... in marine mammals, brains reveals that these animals are ... DDTs and PCBs, as well as emerging contaminants such ... lead author on the study currently in press and ... performed the research as a student in the Woods ...
... radio landscape has made it tough for Foghat to get ... to new research published in The American Naturalist . ... that the songs of white-crowned sparrows change over time in ... factors that drive the evolution of mating signals in birds. ...
... Institutes of Health is launching the first integrated, ... rare and neglected diseases. The $24 million program ... Rare and Neglected Diseases Program, or TRND. ... is unusual because TRND creates a drug development ...
Cached Biology News:Skip this cocktail party 2Skip this cocktail party 3Bird songs change with environment 2NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Request Info...
Request Info...
Request Info...
Biology Products: